Table 2.

Number of colorectal cancer and adenoma cases and controls, odds ratios, and 95% CI for MTHFR 677C>T and MTHFR 1298A>C, stratified by study

Colorectal cancer
Colorectal adenoma
Controls, n (%)Cases, n (%)OR (95% CI)PControls, n (%)Cases, n (%)OR (95% CI)P
MTHFR 677592490296308
    CC271 (45.8)238 (48.6)1.00130 (43.9)135 (43.8)1.00
    CT272 (46.0)199 (40.6)0.83 (0.65-1.07)0.16139 (47.0)132 (42.9)0.91 (0.65-1.28)0.61
    TT49 (8.3)53 (10.8)1.23 (0.80-1.89)0.3427 (9.1)41 (13.3)1.46 (0.85-2.51)0.17
    Overall test0.130.23
    Overall trend0.99 (0.83-1.19)0.951.10 (0.87-1.40)0.43
    CC/CT vs TT543 (91.7)437 (89.2)1.34 (0.89-2.02)0.16269 (90.9)267 (86.7)1.53 (0.91-2.56)0.11
Males322297174221
    CC147 (45.7)159 (53.5)1.0068 (39.1)99 (44.8)1.00
    CT150 (46.6)116 (39.1)0.71 (0.51-0.99)0.0590 (51.7)93 (42.1)0.71 (0.47-1.08)0.11
    TT25 (7.8)22 (7.4)0.81 (0.44-1.51)0.5116 (9.2)29 (13.1)1.24 (0.63-2.47)0.53
    Overall test0.140.13
    Overall trend0.81 (0.63-1.04)0.100.96 (0.71-1.29)0.79
    CC/CT vs TT297 (92.2)275 (92.6)0.95 (0.52-1.72)0.87158 (9.2)192 (86.9)1.49 (0.78-2.84)0.23
Females27019312287
    CC124 (45.9)79 (40.9)1.0062 (50.8)36 (41.4)1.00
    CT122 (45.2)83 (43.0)1.07 (0.72-1.59)0.7549 (40.2)39 (44.8)1.37 (0.76-2.47)0.29
    TT24 (8.9)31 (16.1)2.03 (1.11-3.71)0.0211 (9.0)12 (13.8)1.88 (0.75-4.69)0.17
    Overall test0.060.32
    Overall trend1.31 (0.99-1.72)0.061.37 (0.91-2.07)0.13
    CC/CT vs TT246 (91.1)162 (83.9)1.96 (1.11-3.46)0.02111 (91.0)75 (86.2)1.61 (0.68-3.85)0.28
MTHFR 1298593488296308
    AA288 (48.6)231 (47.3)1.00140 (47.3)155 (50.3)1.00
    AC259 (43.7)200 (41.0)0.96 (0.75-1.24)0.77130 (43.9)124 (40.3)0.86 (0.62-1.21)0.39
    CC46 (7.8)57 (11.7)1.54 (1.01-2.36)0.0526 (8.8)29 (9.4)1.01 (0.57-1.79)0.98
    Overall test0.090.66
    Overall trend1.13 (0.94-1.35)0.200.94 (0.74-1.21)0.65
    AA/AC vs CC547 (92.2)431 (88.3)1.57 (1.05-2.37)0.03270 (91.2)279 (90.6)1.08 (0.62-1.88)0.79
Males323296174221
    AA158 (48.9)125 (42.2)1.0085 (48.9)113 (51.1)1.00
    AC150 (46.4)133 (44.9)1.12 (0.80-1.56)0.5078 (44.8)84 (38.0)0.81 (0.53-1.23)0.32
    CC15 (4.6)38 (12.8)3.20 (1.68-6.09)<0.00111 (6.3)24 (10.9)1.64 (0.76-3.53)0.21
    Overall test0.0010.18
    Overall trend1.45 (1.13-1.86)0.0041.06 (0.78-1.43)0.73
    AA/AC vs CC308 (95.4)258 (87.2)3.02 (1.63-5.62)<0.001163 (93.7)197 (89.1)1.81 (0.86-3.80)0.12
Females27019212287
    AA130 (48.2)106 (55.2)1.0055 (45.1)42 (48.3)1.00
    AC109 (40.4)67 (34.9)0.75 (0.51-1.12)0.1652 (42.6)40 (46.0)1.01 (0.57-1.79)0.98
    CC31 (11.5)19 (9.9)0.75 (0.40-1.41)0.3715 (12.3)5 (5.8)0.44 (0.15-1.30)0.14
    Overall test0.330.28
    Overall trend0.83 (0.63-1.09)0.180.79 (0.52-1.22)0.29
    AA/AC vs CC239 (88.5)173 (90.1)0.85 (0.46-1.55)0.59107 (87.7)82 (94.3)0.44 (0.15-1.25)0.12
  • NOTE: Cancer study: likelihood ratio test for interaction between sex and MTHFR 677 using the trend model (likelihood ratio χ2(1) = 6.31; P = 0.01). Adenoma study: likelihood ratio test for interaction between sex and MTHFR 677 using the trend model (likelihood ratio χ2(1) = 1.89; P = 0.17). Cancer study: likelihood ratio test for interaction between sex and MTHFR 1298 using the trend model (likelihood ratio χ2(1) = 8.78; P = 0.003). Adenoma study: likelihood ratio test for interaction between sex and MTHFR 1298 using the trend model (likelihood ratio χ2(1) = 1.14; P = 0.29).

    Abbreviation: OR, odds ratio.